Skip to main content
Journal cover image

Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the Severe Typhoid in Africa programme): a population-based study.

Publication ,  Journal Article
Marks, F; Im, J; Park, SE; Pak, GD; Jeon, HJ; Wandji Nana, LR; Phoba, M-F; Mbuyi-Kalonji, L; Mogeni, OD; Yeshitela, B; Panzner, U; Beyene, T ...
Published in: Lancet Glob Health
April 2024

BACKGROUND: Typhoid Fever remains a major cause of morbidity and mortality in low-income settings. The Severe Typhoid in Africa programme was designed to address regional gaps in typhoid burden data and identify populations eligible for interventions using novel typhoid conjugate vaccines. METHODS: A hybrid design, hospital-based prospective surveillance with population-based health-care utilisation surveys, was implemented in six countries in sub-Saharan Africa. Patients presenting with fever (≥37·5°C axillary or ≥38·0°C tympanic) or reporting fever for three consecutive days within the previous 7 days were invited to participate. Typhoid fever was ascertained by culture of blood collected upon enrolment. Disease incidence at the population level was estimated using a Bayesian mixture model. FINDINGS: 27 866 (33·8%) of 82 491 participants who met inclusion criteria were recruited. Blood cultures were performed for 27 544 (98·8%) of enrolled participants. Clinically significant organisms were detected in 2136 (7·7%) of these cultures, and 346 (16·2%) Salmonella enterica serovar Typhi were isolated. The overall adjusted incidence per 100 000 person-years of observation was highest in Kavuaya and Nkandu 1, Democratic Republic of the Congo (315, 95% credible interval 254-390). Overall, 46 (16·4%) of 280 tested isolates showed ciprofloxacin non-susceptibility. INTERPRETATION: High disease incidence (ie, >100 per 100 000 person-years of observation) recorded in four countries, the prevalence of typhoid hospitalisations and complicated disease, and the threat of resistant typhoid strains strengthen the need for rapid dispatch and implementation of effective typhoid conjugate vaccines along with measures designed to improve clean water, sanitation, and hygiene practices. FUNDING: The Bill & Melinda Gates Foundation.

Duke Scholars

Published In

Lancet Glob Health

DOI

EISSN

2214-109X

Publication Date

April 2024

Volume

12

Issue

4

Start / End Page

e599 / e610

Location

England

Related Subject Headings

  • Vaccines
  • Typhoid Fever
  • Prospective Studies
  • Nigeria
  • Madagascar
  • Incidence
  • Humans
  • Ghana
  • Ethiopia
  • Democratic Republic of the Congo
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Marks, F., Im, J., Park, S. E., Pak, G. D., Jeon, H. J., Wandji Nana, L. R., … Rakotozandrindrainy, R. (2024). Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the Severe Typhoid in Africa programme): a population-based study. Lancet Glob Health, 12(4), e599–e610. https://doi.org/10.1016/S2214-109X(24)00007-X
Marks, Florian, Justin Im, Se Eun Park, Gi Deok Pak, Hyon Jin Jeon, Lady Rosny Wandji Nana, Marie-France Phoba, et al. “Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the Severe Typhoid in Africa programme): a population-based study.Lancet Glob Health 12, no. 4 (April 2024): e599–610. https://doi.org/10.1016/S2214-109X(24)00007-X.
Marks, Florian, et al. “Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the Severe Typhoid in Africa programme): a population-based study.Lancet Glob Health, vol. 12, no. 4, Apr. 2024, pp. e599–610. Pubmed, doi:10.1016/S2214-109X(24)00007-X.
Marks F, Im J, Park SE, Pak GD, Jeon HJ, Wandji Nana LR, Phoba M-F, Mbuyi-Kalonji L, Mogeni OD, Yeshitela B, Panzner U, Cruz Espinoza LM, Beyene T, Owusu-Ansah M, Twumasi-Ankrah S, Yeshambaw M, Alemu A, Adewusi OJ, Adekanmbi O, Higginson E, Adepoju A, Agbi S, Cakpo EG, Ogunleye VO, Tunda GN, Ikhimiukor OO, Mbuyamba J, Toy T, Agyapong FO, Osei I, Amuasi J, Razafindrabe TJL, Raminosoa TM, Nyirenda G, Randriamampionona N, Seo HW, Seo H, Siribie M, Carey ME, Owusu M, Meyer CG, Rakotozandrindrainy N, Sarpong N, Razafindrakalia M, Razafimanantsoa R, Ouedraogo M, Kim YJ, Lee J, Zellweger RM, Kang SSY, Park JY, Crump JA, Hardy L, Jacobs J, Garrett DO, Andrews JR, Poudyal N, Kim DR, Clemens JD, Baker SG, Kim JH, Dougan G, Sugimoto JD, Van Puyvelde S, Kehinde A, Popoola OA, Mogasale V, Breiman RF, MacWright WR, Aseffa A, Tadesse BT, Haselbeck A, Adu-Sarkodie Y, Teferi M, Bassiahi AS, Okeke IN, Lunguya-Metila O, Owusu-Dabo E, Rakotozandrindrainy R. Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the Severe Typhoid in Africa programme): a population-based study. Lancet Glob Health. 2024 Apr;12(4):e599–e610.
Journal cover image

Published In

Lancet Glob Health

DOI

EISSN

2214-109X

Publication Date

April 2024

Volume

12

Issue

4

Start / End Page

e599 / e610

Location

England

Related Subject Headings

  • Vaccines
  • Typhoid Fever
  • Prospective Studies
  • Nigeria
  • Madagascar
  • Incidence
  • Humans
  • Ghana
  • Ethiopia
  • Democratic Republic of the Congo